We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+19.04%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$10.4M
Cap. Flow
-$1.89M
Cap. Flow %
-1.26%
Top 10 Hldgs %
95.58%
Holding
19
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$1.85M
2
ZSAN
Zosano Pharma Corporation
ZSAN
+$24K
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$16K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$60.3M 40.05%
6,068,125
– –
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.69B
$24.6M 16.36%
1,025,000
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$13.6M 9.04%
1,332,485
– –
GLUE icon
4
Monte Rosa Therapeutics
GLUE
$1.4B
$12M 7.99%
1,472,331
– –
ACRS icon
5
Aclaris Therapeutics
ACRS
$726M
$9.99M 6.63%
634,455
– –
BMEA icon
6
Biomea Fusion
BMEA
$84.6M
$7.81M 5.19%
798,757
– –
NUVB icon
7
Nuvation Bio
NUVB
$2.2B
$5.69M 3.78%
2,541,009
– –
PSTX
8
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.68M 2.45%
1,043,267
– –
ELEV
9
DELISTED
Elevation Oncology
ELEV
$3.2M 2.13%
2,834,910
– –
OKUR
10
OnKure Therapeutics
OKUR
$154M
$2.97M 1.97%
88,608
– –
SPRB
11
Spruce Biosciences
SPRB
$118M
$1.65M 1.1%
16,073
– –
VIRX
12
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.23M 0.82%
288,571
– –
MRKR icon
13
Marker Therapeutics
MRKR
$18.8M
$1.16M 0.77%
314,286
– –
SYRE icon
14
Spyre Therapeutics
SYRE
$8.54B
$890K 0.59%
67,646
– –
TECX
15
Tectonic Therapeutic
TECX
$529M
$646K 0.43%
84,148
– –
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$609K 0.4%
387,653
– –
TRML
17
DELISTED
Tourmaline Bio
TRML
$460K 0.31%
17,500
-50,792
-74% -$1.85M
ZSAN
18
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-77,663
Closed -$24K
NBRV
19
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-3,600
Closed -$16K

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Aisling Capital Management held 19 positions worth $151M, up 7.4% from $140M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Aisling Capital Management's Q3 2022 filing shows 1 reduced and 2 closed positions. The largest sale was Tourmaline Bio, an estimated $1.85M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's biggest Q3 2022 reduction was Tourmaline Bio, cutting an estimated $1.85M.
  • Aisling Capital Management fully exited Zosano Pharma Corporation in Q3 2022, selling an estimated $24K.
  • Aisling Capital Management's ten largest holdings make up 96% of its $151M portfolio in Q3 2022.
  • Aisling Capital Management opened 0 new positions and closed 2 in Q3 2022.
  • Aisling Capital Management's portfolio value rose 7.4% quarter-over-quarter to $151M.

Based on Aisling Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.